In fact, obesity has significant consequences, including an increased possibility of chronic diseases, including diabetes, heart disease, as well as some types of cancer, and a lower quality of life and self-esteem
(A head-to-head trial of the two medications, funded by Eli Lilly, found that patients on Zepbound lost an average of 20 percent of their weight, versus about 14 percent for those on Wegovy.) Nevertheless, its much harder to get Zepbound than Wegovy
Yue W, Li Y, Ou D, Yang Q: The GLP-1 receptor agonist liraglutide protects against oxidized LDL-induced endothelial inflammation and dysfunction via KLF2
H.GuilakF
L-Citrulline Malate
Abstract Body-protective compound (BPC) 157 demonstrates protective effects against damage to various organs and tissues